NASDAQ:PTGX Protagonist Therapeutics (PTGX) News Today $16.68 -0.45 (-2.63%) (As of 09/29/2023 08:53 PM ET) Add Compare Share Share Today's Range$16.33▼$17.3150-Day Range$16.68▼$20.3752-Week Range$7.24▼$30.10Volume1.39 million shsAverage Volume1.21 million shsMarket Capitalization$959.60 millionP/E RatioN/ADividend YieldN/APrice Target$37.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineProtagonist Therapeutics (NASDAQ:PTGX) Cut to "Sell" at StockNews.comamericanbankingnews.com - September 30 at 3:20 AMProtagonist Therapeutics (NASDAQ:PTGX) Lowered to "Sell" at StockNews.commarketbeat.com - September 30 at 3:18 AMProtagonist Therapeutics (NASDAQ:PTGX) Price Target Cut to $34.00 by Analysts at JPMorgan Chase & Co.americanbankingnews.com - September 26 at 3:40 AMProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 3.9% on Analyst Downgradeamericanbankingnews.com - September 26 at 1:32 AMJP Morgan Maintains Protagonist Therapeutics (PTGX) Overweight Recommendationmsn.com - September 26 at 12:54 AMProtagonist Therapeutics (NASDAQ:PTGX) Price Target Lowered to $34.00 at JPMorgan Chase & Co.marketbeat.com - September 25 at 7:52 AMProtagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at StockNews.comamericanbankingnews.com - September 24 at 1:42 AMProtagonist Therapeutics (NASDAQ:PTGX) Lifted to Hold at StockNews.commarketbeat.com - September 23 at 12:12 AM41,818 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Bought by Financial Enhancement Group LLCmarketbeat.com - September 13 at 5:04 AMBVF Inc. IL Buys Shares of 3,775,900 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - September 12 at 4:39 AMProtagonist Therapeutics to Present at Upcoming Investor Conferencesfinance.yahoo.com - September 5 at 9:23 AMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Russell Investments Group Ltd.marketbeat.com - August 27 at 4:16 AMFederated Hermes Inc. Has $682,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - August 22 at 4:38 AMConnor Clark & Lunn Investment Management Ltd. Sells 72,680 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - August 21 at 5:54 AMGreat Lakes Advisors LLC Makes New $3.46 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - August 20 at 5:50 AMProtagonist Therapeutics (NASDAQ:PTGX) Receives New Coverage from Analysts at StockNews.commarketbeat.com - August 17 at 3:32 AMProtagonist Therapeutics, Inc.: Protagonist Receives $34 Million from Warrant Exercisesfinanznachrichten.de - August 9 at 10:17 AMProtagonist Receives $34 Million from Warrant Exercisesfinance.yahoo.com - August 9 at 10:17 AMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Barclays PLCmarketbeat.com - August 8 at 6:11 AMAnalysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), Dynavax (DVAX)markets.businessinsider.com - August 4 at 7:26 PMHC Wainwright Reaffirms Buy Rating for Protagonist Therapeutics (NASDAQ:PTGX)marketbeat.com - August 4 at 11:01 AMProtagonist Therapeutics, Inc.: Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - August 3 at 6:06 PMProtagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 3 at 6:06 PMPTGX - Protagonist Therapeutics, Inc.finance.yahoo.com - July 22 at 5:22 PM17,285 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by CM Wealth Advisors LLCmarketbeat.com - July 21 at 7:29 AMMackenzie Financial Corp Buys Shares of 27,504 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - July 20 at 4:30 AMProtagonist Therapeutics, Inc.: Protagonist Therapeutics Reports Granting of Inducement Awardfinanznachrichten.de - July 18 at 7:13 PMAnalysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and KalVista Pharmaceuticals (KALV)markets.businessinsider.com - July 10 at 8:20 AMJMP Securities Maintains Protagonist Therapeutics (PTGX) Market Outperform Recommendationmsn.com - July 6 at 5:45 PMExpert Ratings for Protagonist Therapeuticsmsn.com - July 6 at 5:45 PMAnalyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressivemarkets.businessinsider.com - July 6 at 5:45 PMJMP Securities Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)markets.businessinsider.com - July 5 at 8:34 PMProtagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatmentfinance.yahoo.com - July 5 at 10:33 AMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Boosted by Allspring Global Investments Holdings LLCmarketbeat.com - July 5 at 4:23 AMPiper Sandler Reiterates Protagonist Therapeutics (PTGX) Overweight Recommendationmsn.com - July 4 at 5:37 PMBTIG Reiterates Protagonist Therapeutics (PTGX) Buy Recommendationmsn.com - July 4 at 5:37 PMAnalysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Protagonist Therapeutics (PTGX) and Arcus Biosciences (RCUS)markets.businessinsider.com - July 4 at 7:30 AMProtagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasisfinance.yahoo.com - July 4 at 7:30 AMProtagonist Therapeutics (NASDAQ: PTGX)fool.com - July 3 at 3:00 PMAstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Mondaybenzinga.com - July 3 at 11:03 AMmarketbeat.com - July 3 at 9:37 AMProtagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Whyfinance.yahoo.com - June 30 at 1:06 PMGratus Capital LLC Has $4.87 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - June 30 at 12:45 PMAre (More) Big Gains Ahead for This Small Cap Biotech Stock? (PTGX)marketbeat.com - June 28 at 8:57 AMWall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Knowmsn.com - June 15 at 2:30 PMWall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Knowfinance.yahoo.com - June 15 at 2:30 PMHere's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep goingfinance.yahoo.com - June 13 at 5:21 PMClinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PVfinance.yahoo.com - June 9 at 12:49 PMProtagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congressfinance.yahoo.com - June 6 at 9:32 AMUBS Group AG Increases Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - June 4 at 4:30 AM Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Media Mentions By Week PTGX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼-0.260.69▲Average Medical News Sentiment PTGX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼82▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: REGENXBIO News OmniAb News Zymeworks News Cibus News Aura Biosciences News KalVista Pharmaceuticals News Ocular Therapeutix News Xenon Pharmaceuticals News Zai Lab News Avadel Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:PTGX) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.